Controlled release fumarate esters
View Patent ↗Described herein are pharmaceutical compositions comprising fumarate esters, methods for making the same, and methods for treating subjects in need thereof. In particular, oral pharmaceutical compositions comprising controlled release fumarate esters are described.
1. An oral pharmaceutical composition comprising one or more fumarate esters suspended in a matrix comprising a lipid or lipophilic vehicle at a weight ratio of fumarate ester to matrix from about 1:1 to about 1:5, wherein the lipid or lipophilic vehicle comprises a mixture of mono- and di-glycerides, polyvinylpyrrolidone, and polyoxyl 40 hydrogenated castor oil.
2. The composition of claim 1 , wherein the fumarate ester comprises dimethyl fumarate, monomethyl fumarate, or a combination thereof.
3. The composition of claim 1 , wherein the matrix further comprises lactic acid.
4. The composition of claim 1 , wherein the pharmaceutical composition comprises:
about 20% to about 50% by weight of one or more fumarate esters;
about 18% to about 70% by weight of a mixture of mono- and di-glycerides;
about 1% to about 10% by weight polyvinylpyrrolidone; and
about 2% to about 12% by weight polyoxyl 40 hydrogenated castor oil.
5. The composition of claim 4 , wherein the pharmaceutical composition further comprises about 1% to about 5% lactic acid.
6. The composition of claim 1 , wherein the pharmaceutical composition comprises:
about 28% by weight of one or more fumarate esters;
about 54% by weight of a mixture of mono- and di-glycerides;
about 3% by weight polyvinylpyrrolidone; and
about 10% by weight polyoxyl 40 hydrogenated castor oil.
7. The composition of claim 6 , wherein the pharmaceutical composition further comprises about 5% lactic acid.
8. The composition of claim 1 , wherein the fumarate ester comprises an amount of about 100 mg to about 230 mg.
9. The composition of claim 1 , wherein the fumarate ester comprises an amount of about 100 mg to about 115 mg.
10. The composition of claim 1 , wherein the fumarate ester comprises an amount of about 200 mg to about 230 mg.
11. The composition of claim 1 , wherein the fumarate ester comprises milled or micronized particles with a particle size distribution with a d90 of less than 100 μm (PSD d90≦100 μm).
12. The composition of claim 1 , wherein the fumarate ester comprises dimethyl fumarate.
13. The composition of claim 1 , wherein the fumarate ester comprises monomethyl fumarate.
14. The composition of claim 1 , wherein the pharmaceutical composition prevents sublimation of the fumarate ester during manufacturing.
15. The composition of claim 1 , wherein the pharmaceutical composition reduces flushing or gastrointestinal side effects.
16. The composition of claim 1 , wherein the pharmaceutical composition is stable for at least 1 year at 25° C.
17. The composition of claim 1 , wherein the pharmaceutical composition is encapsulated in a soft capsule.
18. The composition of claim 1 , wherein the pharmaceutical composition is encapsulated in an enteric soft capsule.
19. A method for manufacturing an oral pharmaceutical composition comprising:
(i) providing a lipid or lipophilic matrix fill comprising a suspension of one or more fumarate esters at a weight ratio of fumarate ester to matrix from about 1:1 to about 1:5, wherein the lipid or lipophilic matrix fill comprises a mixture of mono- and di-glycerides, polyvinylpyrrolidone, and polyoxyl 40 hydrogenated castor oil;
(ii) providing a soft capsule shell composition;
(iii) casting the soft capsule shell composition into films using heat-controlled drums or surfaces; and
(iv) forming a soft capsule comprising the lipid or lipophilic matrix fill using rotary die encapsulation technology.
20. A pharmaceutical compositions comprising a soft capsule shell encapsulating a lipid or lipophilic matrix comprising one or more fumarate esters produced by the method of claim 19 .
21. The composition of claim 20 , wherein the fumarate ester comprises dimethyl fumarate, monomethyl fumarate, or a combination thereof.